The mechanisms of delayed onset type adverse reactions to oseltamivir

Infectious Diseases

Volumn 48, Issue 9, 2016, Pages 651-660

  Hama, Rokuro ^a  

^a Satoyama Kurabu   (Japan)

Author keywords

Antibody; Endogenous neuraminidase; Oseltamivir; Pro inflammatory cytokines; QT prolongation; Renal Impairment

Indexed keywords

GAMMA INTERFERON; GANGLIOSIDE; INTERLEUKIN 6; OSELTAMIVIR; SIALIDASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; ANTIVIRUS AGENT; CYTOKINE; GLUCOSE BLOOD LEVEL;

ADVERSE DRUG REACTION; ANTIBODY PRODUCTION; BRADYCARDIA; GENE; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HYPERGLYCEMIA; INFLUENZA; KIDNEY DISEASE; MENTAL DISEASE; NEURAMINIDASE GENE; NONHUMAN; QT PROLONGATION; REVIEW; SIDE EFFECT; T LYMPHOCYTE; VIRAL CLEARANCE; ANIMAL; BLOOD; DRUG EFFECTS; FERRET; GLUCOSE BLOOD LEVEL; HEART RATE; METABOLISM; MOUSE; PATHOPHYSIOLOGY; RAT;

ANIMALS; ANTIVIRAL AGENTS; BLOOD GLUCOSE; CYTOKINES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FERRETS; HEART RATE; HUMANS; MICE; OSELTAMIVIR; RATS;

EID: 84982272572     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.1080/23744235.2016.1189592     Document Type: Review

References (68)

1. CDC. Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 [Internet]; [cited 2016 Mar 23]. Available from: http://www.cdc.gov/h1n1flu/recommendations.htm
2. CDC. Influenza antiviral medications: summary for clinicians, (last updated Feb 25 2015) [Internet]; [cited 2016 Mar 23]. Available from: http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm#modalIdString_CDCTable_1
3. World Health Organization. WHO Model List of Essential Medicines.19th edition (May 2015) [Internet]; [cited 2016-03-23]. Available from: http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf?ua ¼1
4. Maxwell SR. Tamiflu and neuropsychiatric disturbance in adolescents. BMJ. 2007;334:1232-1233
5. Hama R. Discussion of the causal relationship between oseltamivir phosphate (Tamiflu), and sudden death and death from abnormal behavior. Paper presented at the session of Japanese Society for Pediatric Infectious Diseases in Tsu, Mie Prefecture (held on 2005- 11-12) [Internet]; [cited 2016 Mar 23]. Available from: http://www.npojip.org/english/no59.html.
6. Hama R. Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationships. Intern J Risk Safety Med. 2008;20:5-36
7. Hama R. Oseltamivir’s adverse reactions: fifty sudden deaths may be related to central suppression. BMJ. 2007;335:59
8. Hama R, Jones M, Hayashi K, et al. Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/ H1N1 influenza. Int J Risk Saf Med. 2011;23:201-215
9. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;4: CD008965
10. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012;1: CD008965
11. Kohno S, Yen MY, Cheong HJ, et al. (S-021812 Clinical Study Group), et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother. 2011;55:5267-5276
12. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010;54:2575-2582
13. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis. 2009;48:S3-S1
14. Roche. Media release: Roche donates a further 2 million treatment courses of antiviral Tamiflu to the WHO for regional stockpiling (2006 Jan 17) [Internet]; [cited 2016-03-23]. Available from: www.roche.com/med-cor-2006-01-17.rtf
15. Jack A. Roche steps up production of Tamiflu after virus scare. Financial Times. 13 May 2009; p. 17
16. Hoffmann-La Roche Inc. FDA Pediatric advisory committee briefing document for Tamiflu (2007) [Internet]; ‘cited 2016 Mar 23]. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4325b_02_15_Sponsor%20Background%20Package%20Roche.pdf.
17. Glaxosmithkline FDA Pediatric Advisory Committee Meeting RelenzaVR (zanamivir) Inhalation Powder. Sponsor Backgrounder (Briefing Information) (2007-11-27) [Internet]; [cited 2016 Mar 23]. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4325b_02_16_Sponsor%20Background%20Package%20GSK.pdf.
18. Ministry of Health, Labor and Welfare (MHLW): advisory panel for drug safety (held on 2014-10-29), usage review of neuraminidase inhibitors (in Japanese) [Internet]; [cited 2016 Mar 23]. Available from: http://www.mhlw.go.jp/file/05-Shingikai-11121000-Iyakushokuhinkyoku-Soumuka/0000063406.pdf.
19. Bhatia A, Kast RE. How influenza’s neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency. Cell Mol Biol Lett. 2007;12:111-119
20. Matrosovich MN, Matrosovich TY, Gray T, et al. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol. 2004;78:12665-12667
21. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353:1363-1373
22. Ohuchi M, Asaoka N, Sakai T, et al. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect. 2006;8:1287-1293
23. Liu C, Eichelberger MC, Compans RW, et al. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol. 1995;69:1099-1106
24. Full prescription information of oseltamivir (revised in April 2010) [Internet]; [cited 2016-03-23]. Available from: http://www.accessdata. fda.gov/drugsatfda_docs/label/2011/021087s057lbl.pdf
25. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282:1240-1246
26. Morimoto K, Nakakariya M, Shirasaka Y, et al. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab Dispos. 2008;36:6-9
27. Ose A, Kusuhara H, Yamatsugu K, et al. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab Dispos. 2008;36:427-434
28. MHLW. Documents for the fifth 2007 advisory Panel on Drug Safety (held on 2007-12-25) (in Japanese) [Internet]; [cited 2016 Mar 23]. Available from: http://www.mhlw.go.jp/shingi/2007/12/s1225-7.html.
29. Japanese SBA. Tamiflu capsule for treatment [Internet]; [cited 2016 Mar 23]. Available from: http://www.pmda.go.jp/drugs/2000/g001202/index.html.
30. PMDA. Examination results by PMDA (Tamiflu capsule for treatment) [Internet]; [cited 2016 Mar 23]. Available from: http://www.pmda.go.jp/drugs/2000/g001202/70repo01.pdf.
31. Hama R, Bennet C. The mechanisms of sudden-onset type adverse reactions to oseltamivir. Acta Neurologica Scandinavica (revised for publication).
32. Sawabuchi T, Suzuki S, Iwase K, et al. Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza. Respirology. 2009;14:1173-1179
33. Shinahara W, Takahashi E, Sawabuchi T, et al. Immunomodulator clarithromycin enhances mucosal and systemicimmune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis. PLoS One. 2013;8:e70060
34. Takahashi E, Kataoka K, Fujii K, et al. Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. Microbes Infect. 2010;12:778-783
35. Takahashi E, Kataoka K, Indalao IL, et al. Oral clarithromycin enhances airway immunoglobulin A (IgA) immunity through induction of IgA class switching recombination and B-cell-activating factor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with influenza A virus. J Virol. 2012;86:10924-10934
36. Cox RJ, Mykkeltvedt E, Sjursen H, et al. The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine. 2001;19:4743-4749
37. Fritz RS, Hayden FG, Calfee DP, et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis. 1999;180:586-593
38. Kopel E, Mandelboim M, Amitai Z, et al. Possible recurrent pandemic (H1N1) 2009 infection, Israel. Emerging Infect Dis. 2010;16:1321-1322
39. Perez CM, Ferres M, Labarca JA. Pandemic (H1N1) 2009 reinfection, Chile. Emerging Infect Dis. 2010;16:156-157
40. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry-Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, 2005[Internet]; [cited 2016 Mar 23]. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf.
41. EMA. Marketing Authorization Application, Table of Contents-Volume 81 1007-Brewster M. Ro 64-0802/002 (GS-4071) cardiovascular and respiratory evaluation in the anaesthetized dog following intravenous administrations (DHB08601).RR W-142974 1999 (disclosed document from EMA).
42. Hama R, Jones M, Jefferson T. Concerns about the randomization in the prophylaxis trials of oseltamivir (rapid response), 2015[Internet]; [cited 2016 Mar 23]. Available from: http://www.bmj.com/content/348/bmj.g2545/rr.
43. The Dryad Digital Repository[Internet]; [cited 2016 Mar 23]. Available from: http://datadryad.org/resource/doi:10.5061/dryad.77471
44. Moore ML, Chi MH, Zhou W, et al. Cutting edge: oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity. J Immunol. 2007;178:2651-2654
45. Stamatos NM, Carubelli I, van de Vlekkert D, et al. LPS-induced cytokine production in human dendritic cells is regulated by sialidase activity. J Leukoc Biol. 2010;88:1227-1239
46. Feng C, Zhang L, Almulki L, et al. Endogenous PMN sialidase activity exposes activation epitope on CD11b/CD18 which enhances its binding interaction with ICAM-1. J Leukoc Biol. 2011;90:313-321
47. Marois I, Cloutier A, Garneau É, et al. The administration of oseltamivir results in reduced effector and memory CD8þ T cell responses to influenza and affects protective immunity. FASEB J. 2015;29:973-987
48. Crain SM, Shen KF. Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice. Brain Res. 2004;995:260-266
49. Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother. 1998;42:640-646
50. Onishi M, Kitano M, Taniguchi K, et al. Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae. Antiviral Res. 2015;117:52-59
51. Tanaka A, Nakamura S, Seki M, et al. The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of postinfluenza pneumococcal pneumonia in mice. Antivir Ther. 2015;20:11-19
52. Kitano M, Kodama M, Itoh Y, et al. Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice. Antimicrob Agents Chemother. 2013;57:2286-2294
53. Wong ZX, Jones JE, Anderson GP, et al. Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung. Influenza Other Respir Viruses. 2011;5:343-350
54. Hama R. Pharmacological toxicological clinical and epidemiological evidences of neuropsychiatric adverse reactions to oseltamivir and misleading analysis due to serious miscalculation in Japanese MHLW’s 2006/07 epidemiological study report. (in Japanese). Jap J Clin Pharmacol Therap. 2009;40:13S-14S.
55. Muraki K, Hatano N, Suzuki H, et al. Oseltamivir blocks human neuronal nicotinic acetylcholine receptor-mediated currents. Basic Clin Pharmacol Toxicol. 2014;116:87-95
56. Izumi Y, Tokuda K, O’dell KA, et al. Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci Lett. 2007;426:54-58
57. Izumi Y, Tokuda K, O’Dell K, et al. Synaptic and behavioral interactions of oseltamivir (Tamiflu) with neurostimulants. Hum Exp Toxicol. 2008;27:911-917
58. Lindemann L, Jacobsen H, Schuhbauer D, et al. In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite. Eur J Pharmacol. 2010;628:6-10
59. Hiasa M, Isoda Y, Kishimoto Y, et al. Inhibition of MAO-A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivir. Br J Pharmacol. 2013;169:115-129
60. Yamaguchi K, Hata K, Koseki K, et al. Evidence for mitochondrial localization of a novel human sialidase (NEU4). Biochem J. 2005;390:85-93
61. Yamanami H, Shiozaki K, Wada T, et al. Down-regulation of sialidase NEU4 may contribute to invasive properties of human colon cancers. Cancer Sci. 2007;98:299-307
62. Yoshizumi S, Suzuki S, Hirai M, et al. Increased hepatic expression of ganglioside-specific sialidase, NEU3, improves insulin sensitivity and glucose tolerance in mice. Metab Clin Exp. 2007;56:420-429
63. Shelton MJ, Lovern M, Ng-Cashin J, et al. Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. Antimicrob Agents Chemother. 2011;55:5178-5184
64. GlaxoSmithKline (then GlaxoWelcome) SBA (Relenza/zanamivir) 1999, (in Japanese) [Internet]; [cited 2016 Mar 23]. Available from: http://www.pmda.go.jp/drugs/1999/g991201/index.html.
65. Daiichi-Sankyo. SBA(Inavir/laninamivir) 2010, (in Japanese) [Internet]; [cited 2015 May 27]. Available from: http://www.pmda.go.jp/drugs/2010/P201000050/index.html.
66. Shionogi. SBA (Rapiacta/peramivir) 2010, (in Japanese) [Internet]; [cited 2016 Mar 23]. Available from:http://www.pmda.go.jp/drugs/2010/P201000001/index.html.
67. Chengelis CP, Gad SC. Introduction. In: Gad SC, Chengelis CP, editors. Animal models in toxicology. New York: Marcel Dekker Inc; 1992. p. 1-20
68. Burrell GA. The use of mice and birds for detecting carbon monoxide after mine fire and explosion. Technical Paper 11, Washington (DC): Department of Interior, Beureau of Mines; 1912. p. 3-16.